Abstract
Objective Current understanding of cognitive functioning in body dysmorphic disorder (BDD) is limited, owing to few studies, small sample sizes, and assessment across only limited cognitive domains. Existing research has also shown inconsistent findings, with both intact and impaired cognition reported in BDD, which might point toward cognitive heterogeneity in the disorder. This study aimed to examine the cognitive profile of BDD in a large sample across eight cognitive domains, and to explore whether cognitive subgroups might be identified within BDD.
Methods Cognitive domains of inhibition/flexibility, working memory, speed of processing, reasoning and problem-solving, visual and verbal learning, attention/vigilance and social cognition were assessed and compared between 65 BDD patients and 70 healthy controls. Then, hierarchical clustering analysis was conducted on the BDD group’s cognitive data.
Results Group-average comparisons demonstrated significantly poorer cognitive functioning in BDD than healthy controls in all domains except for attention/vigilance and social cognition. Cluster analysis identified two divergent cognitive subgroups within our BDD cohort characterised by i) broadly intact cognitive function with mild selective impairments (72.3%), and ii) broadly impaired cognitive function (27.7%). However, the clusters did not significantly differ on clinical parameters or most sociodemographic characteristics.
Conclusion Cognitively diverse subgroups were identified within BDD, yet these were obscured in group-average comparisons. However, subgroup profiles of cognitive functioning seem unrelated to the clinical presentation of BDD. Further research into the underlying mechanisms of cognition in BDD is warranted.
Significant Outcomes
Cognitive function varies widely among people with body dysmorphic disorder (BDD) and includes subgroups characterised by broadly intact or broadly impaired cognitive profiles.
However, reduced performances in visual learning and working memory as relative to healthy participants were identified across both BDD cognitive subgroups to differing degrees.
Clinical characteristics were not significantly different among the two BDD cognitive subgroups; what role cognitive functioning may play in the aetiology or presentation of BDD remains unclear.
Limitations
The output of clustering analysis is sensitive to the choice of variables entered and requires replication with analogous measures of cognition.
Psychiatric comorbidities and medications could have impacted cognitive performances in the BDD group in an unaccounted-for manner.
Data availability statement Author elects to not share data.
Competing Interest Statement
Dr. Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, Seqirus; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness and is part owner of Clarity Healthcare. He is on the boards of both Mind Medicine Australia and The Mental Health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company. All other authors report no financial relationships with commercial interests and no conflicts of interest.
Funding Statement
A.M, S.B, S.A.G, and T.P were supported by Australian Government Research Training Program Scholarships during this research. W.L.T holds a National Health and Medical Research Council (NHMRC) grant (GNT1161609). S.L.R holds a Senior NHMRC Fellowship (GNT1154651). This study was funded in part by a Monash Strategic Grant, a Barbara Dicker Brain Sciences Foundation Grant, and an Australian Catholic University Research Fund grant (ACURF2013000557).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All research procedures contributing to this work were approved by hospital and university human research ethics committees (Alfred Hospital, St Vincent's Hospital, Australian Catholic University, and Swinburne University of Technology) and complied with by the Declaration of Helsinki of 1975, as revised in 2008.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration of Interest: Dr. Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag,Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier, Seqirus; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova. He is founder of the Optimal Health Program, currently operating as Optimal Wellness and is part owner of Clarity Healthcare. He is on the boards of both Mind Medicine Australia and The Mental Health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company. All other authors report no financial relationships with commercial interests and no conflicts of interest.
Data Availability
The data is not available for sharing.